Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $2.66 per share which beat the analyst consensus estimate of $1.03 by 158.5 percent. This is a 192.31 percent increase over earnings of $0.91 per share from the same period last year. The company reported quarterly sales of $97.800 million which beat the analyst consensus estimate of $93.186 million by 4.95 percent. This is a 16.65 percent increase over sales of $83.841 million the same period last year.